A5374
Brief description of study
A5374 is a phase I/IIa randomized, two-arm, double-blind placebocontrolled, multi-step strategy trial to evaluate safety and efficacy of therapeutic vaccination with chimpanzee adenovirus (ChAdV)- and poxvirus modified vaccinia Ankara (MVA)-vectored vaccines in a sequential regimen with the Toll-like Receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) in individuals with HIV-1 who started suppressive (ART) during acute HIV-1.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or